A cura di:
POLA AnnalisaPOLI Maura
The invention relates to a new medical application of sulphated glycosaminoglycans, particularly heparin, low molecular weight heparin and derivatives thereof, in the therapeutic treatment of anaemia, in particular iron deficiency anaemia, chronic disease anaemia (also known as inflammatory anaemia) and iron-refractory iron-deficient anaemia (IRIDA). The mechanism underlying the new medical application is the ability of the aforementioned sulphated glycosaminoglycans to inhibit or reduce the levels of expression of hepcidin, a hepatic molecule which plays a central role in regulating systemic iron homeostasis.
Anni di svolgimento: 2009 – 2029
Record ID: 386